|
National Research Corporation (NASDAQ: NRC) |
|
National Research Corporation
NRC's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
National Research's sales fell
by -5.6 % in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 1358
Medical Laboratories industry recorded
growth of revenues by 6.58 %
National Research's net profit decreased by -27.78 % in III. Quarter 2024 year on year, to $6 millions.
• More on NRC's Growth
|
|
National Research current PE on trailing twelve month basis is above Medical Laboratories industry average.
National Research realized cash reduction of $ -0.02 per share in trailing twelve-month period. |
Company |
14.74 |
PE TTM
|
Industry |
-0 |
PE TTM
|
|
Company's Price to Sales ratio is at 2.75.
Medical Laboratories industry's Price to Sales ratio is at 2.54.
• More on NRC's Valuation
|
|
|
|
|
National Research current PE on trailing twelve month basis is above Medical Laboratories industry average.
National Research realized cash outflow of $ -0.02per share in trailing twelve-month period. |
Company |
14.74 |
PE TTM
|
Industry |
-0 |
PE TTM
|
|
Company's Price to Sales ratio is at 2.75.
Medical Laboratories industry's Price to Sales ratio is at 2.54.
National Research Price to Book Ratio is at 11.45 lower than Industry Avg. of 29.03. and higher than S&P 500 Avg. of 0.02
• More on NRC's Valuation
|
|
NRC's Profitability Comparisons
|
National Research faced margin deterioration, primarily through cost pressure. Operating Margin fell in III. Quarter 2024 to 22.28 % from 25.31 % in II. Quarter.
National Research net profit margin of 15.88 % is currently ranking no. 2 in Medical Laboratories industry, ranking no. 71 in Healthcare sector and number 914 in S&P 500.
Profitability by Segment |
Total |
15.88 % |
|
|
National Research faced margin deterioration, primarily through cost pressure. Operating Margin fell in III. Quarter 2024 to 22.28 % from 25.31 % in II. Quarter.
National Research net profit margin of 15.88 % is currently ranking no. 2 in Medical Laboratories industry, ranking no. 71 in Healthcare sector and number 914 in S&P 500.
• More on NRC's Key Ratios
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com